|
|
News Breaks | | | | September 20, 2012 | | 06:05 EDT |  | UTHR | United Therapeutics, Ascendis Pharma to work on self-injectable Treprostinil
United Therapeutics announced that it has signed an exclusive agreement with Ascendis Pharma A/S to apply Ascendis Pharma's proprietary TransCon technology platform to United Therapeutics' treprostinil molecule, the active ingredient in Remodulin, or treprostinil, injection. United Therapeutics believes that the TransCon technology platform may enable a controlled, long-acting release of a novel, carrier-linked product, significantly enhancing the delivery profile of treprostinil by establishing a self-injectable alternative for patients who currently use the drug via a continuous infusion pump for the treatment of pulmonary arterial hypertension, or PAH. | |
|
News For UTHR From The Last 14 Days Check below for free stories on UTHR the last two weeks. |
|
|
| There are no results for UTHR |
|
|
|
|
|
|
